News

This is the first new recommendation from the American Academy of Pediatrics since the AIDS epidemic began in the 1980s.

The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi for mantle cell lymphoma. The agency has delay a decision on Dupixent in COPD and has set goal dates for zolbetuximab in gastric cancer and zanidatamab in bile duct cancer.

COBRA coverage is not currently considered creditable coverage, so some seniors face Part B penalties. That needs to change.

Healthcare providers and community leaders won’t need a green thumb to implement these changes.

More than 25% of low-income families' earnings go toward healthcare costs.

Some large randomized trials have suggested that taking low doses of aspirin on a daily basis would be an easy, inexpensive way of lowering the risk of getting age-related macular degeneration. Not so a well-designed, placebo-controlled study of septuagenarians conducted in Australia.

On the heels of Winrevair's approval, Gossamer Bio and the Chiesi Group struck a deal to develop seralutinib.

Researchers find a mismatch between demographics of the neighborhoods where the FQHCs with vision care are located and those using the vision services.

Although bills that would make comprehensive changes to the PBM industry have advanced in Congress, Paul Kelly, a veteran healthcare lobbyist, says a limited version that saves Medicare money may pass as an offsetting "pay for" for extension of more liberal rules for telehealth services that Medicare covers.

Wrong diagnoses were also made in women with dense, fatty breasts.

At the 2024 American Thoracic Society conference, Surya Bhatt, MD, director of the Lung Imaging Lab at the University of Alabama of Birmingham discussed the NOTUS trial, a second phase three trial for treating COPD with type two inflammation using dupilumab, following the BOREAS trial.

Veteran healthcare lobbyist discussed the prospects for the Senate passing comprehensive PBM legislation in the most recent episode of Managed Healthcare's DC Roundtable podcast.

MHE Editors are seeking diverse healthcare professionals from different backgrounds and healthcare sectors, with individual interests. Eligible candidates are early or mid-career leaders with less than 10 years of experience. Award winners will enjoy complimentary passes to the PBMI Annual National Meeting in Orlando, Florida, from Sept. 4-6. Additional perks include a feature in our August issue, a subscription to MHE and more!

Preliminary data suggest people with Group 1 pulmonary hypertension had improved outcomes if they had ever received hormone replacement therapy.

An administration change in November could see the return of closed borders or increased protections for immigrants.

Undocumented individuals are ineligible for the Affordable Care Act (ACA) or federally funded Medicaid, but some states offer state-sponsored coverage for certain immigration statuses, such as Temporary Protected Status.

Immigrant children need a variety of resources when they come to the United States.

HPV vaccine uptake increased almost 20% under guidance from the clinic-based program.

Discrimination, fear and lack of knowledge are just a few of the obstacles they face when trying to access healthcare.

The American Thoracic Society (ATS) has recommended moving to race-neutral equations for assessing what lung functions mean. A study presented at the ATS meeting this weekend projected how the new equation would affect disease classification, lung test standards for becoming a firefighter and VA disability benefits.

Results from a phase 2a study suggest that the benefits of Tezspire (tezepelumab) for people with chronic pulmonary obstructive disease may be limited to those with elevated blood eosinophil counts indicative of type 2 inflammation.

Breast cancer stats from the American Association for Cancer Research 2024 Cancer Disparities Report.

A new study in JAMA Network Open suggests that disparities in outcomes between Black and White children with acute myeloid leukemia may be due to differences in pharmacogenomics, which is how genes affect drug responses.

Results from the phase 3 NOTUS trial presented at the ATS meeting confirm benefits of Dupixent (dupilumab) among 20% to 40% of people with chronic obstructive pulmonary disease (COPD) who have evidence of type 2 inflammation.

Pamrevlumab is the third investigational agent to fail in a phase 3 trials. Researchers said It may be time to stop treating idiopathic pulmonary fibrosis as a single disease and treat subcategories organized by relevant biomarkers.

The update was prompted by a recent increase in breast cancer cases among women in their 40s.